Ocular FIP treatment enters a more practical era

Ocular feline infectious peritonitis is becoming a more practical treatment conversation in general practice and specialty care, not because the disease has changed, but because access to antiviral therapy has. VetGirl’s recent podcast on ocular FIP treatment highlights a 2025 Royal Veterinary College case series while also reminding clinicians that eye disease may be the dominant presenting feature in some cats, with vision changes or ocular inflammation sometimes providing the first clue to systemic FIP. That conversation lands at a moment when U.S. veterinarians can prescribe compounded oral GS-441524 for individual cats, giving clinicians a legal, pharmacy-based path to manage a presentation that was once both devastating and logistically difficult to treat. (fda.gov)

That shift follows several years of rapidly evolving FIP care. GS-441524 and remdesivir transformed expectations for a disease long viewed as almost uniformly fatal, with clinical studies from Australia, the UK, and elsewhere showing meaningful remission rates across effusive, non-effusive, neurologic, and ocular forms. VetGirl’s broader FIP clinical update notes that reported response rates are now reaching roughly 85% to 90% in some settings, a dramatic change from the pre-antiviral era. One widely cited 2023 case series of 32 cats treated with remdesivir and GS-441524 found successful outcomes across multiple FIP presentations, including cats with eye involvement. (academic.oup.com)

Ocular disease remains a special case because drug delivery is harder. In the JVIM series, investigators noted that ocular and neurologic cases required higher starting doses because of limited penetration across the blood-eye and blood-brain barriers. Those cats were started at 15 to 20 mg/kg of remdesivir or oral GS-441524 every 24 hours, and 4 of 6 cats with ocular involvement recovered fully. VetGirl’s ocular FIP review adds useful clinical context here: ocular involvement is seen much more often in non-effusive disease than in effusive disease, and exam findings can include anterior uveitis, keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, fibrinous exudate, retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing. Related expert-facing coverage in dvm360 has echoed that higher dosages may be needed in cases with ocular signs, and that treatment should be adjusted based on clinical response rather than treated as a static, one-size-fits-all protocol. (academic.oup.com)

The regulatory backdrop matters here. On May 10, 2024, the FDA said it did not intend to enforce approval requirements for GS-441524 compounded from bulk drug substances when prescribed by a veterinarian for a specific cat with FIP under the conditions in Guidance for Industry #256. Shortly after, Stokes Pharmacy, working with Bova, announced that a compounded oral formulation would be available in the U.S. beginning June 1, 2024. That didn’t create an FDA-approved FIP drug, but it did give veterinarians a clearer route away from black-market sourcing and toward pharmacy-supported prescribing. VetGirl’s dosing update also points out why that access matters operationally: remdesivir is injectable, while GS-441524 can be compounded into oral tablets, making long courses more feasible for many clients and patients. (fda.gov)

Industry and expert commentary reflects both optimism and restraint. In dvm360’s recent FIP discussion, internist Kelly Chappell said treatment progress has been substantial, even as diagnosis remains frustratingly presumptive in many cases. That aligns with VetGirl’s updated clinical review, which emphasizes that FIP still starts as a pattern-recognition diagnosis built from signalment, risk factors, clinicopathologic changes, imaging, and fluid analysis rather than a single definitive in-clinic test. Another dvm360 clinical update, featuring Sarah Coggins, emphasized the welfare advantage of moving cats to oral therapy and, when possible, avoiding painful injectable regimens altogether. That practical framing matters for ocular FIP, where cats may need prolonged therapy, frequent reassessment, and pet parent coaching to keep treatment on track. (dvm360.com)

Why it matters: For veterinary teams, ocular FIP sits at the intersection of pharmacology, ophthalmology, and client communication. These cases may present with uveitis, hyphema, anisocoria, keratic precipitates, or retinal changes, but the bigger challenge is often operational: making a presumptive diagnosis confidently enough to start treatment, choosing a dose that reflects ocular involvement, and monitoring closely as cats gain weight and clinical signs evolve. The recent availability of compounded oral GS-441524 in the U.S. lowers one major barrier, but it also raises the need for consistent protocols, realistic counseling on duration and cost, and a clear plan for escalation if ocular disease progresses or neurologic signs emerge. VetGirl’s dosing-and-duration review adds another layer: cats often look better within about a week of starting antivirals, but early clinical improvement does not necessarily mean the virus has cleared from sanctuary sites such as the eye or CNS. That is why investigators are exploring more objective treatment-stop criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and the albumin:globulin ratio, especially as the field tries to shorten therapy without increasing relapse risk. (dvm360.com)

There’s also a cautionary note in the newer duration data. A randomized study cited by the ABCD FIP guideline and discussed by Worms & Germs suggests some cats with FIP may do just as well with 6 weeks of oral GS-441524 as with 12 weeks, but that trial focused on effusive disease, with only isolated ocular and neurologic cases included. Worms & Germs specifically warns against broadly extrapolating those results to ocular FIP. VetGirl’s review of a 2025 JSAP paper similarly frames shorter treatment as an active area of refinement, not a settled standard, and links that question to high-dose induction strategies and biomarker-guided treatment termination rather than simple calendar-based shortening. In other words, the field is moving toward shorter, more tailored treatment in some cats, but ocular disease still appears to warrant a more conservative, individualized approach. (abcdcatsvets.org)

What to watch: The next phase will likely center on protocol refinement, especially around dose intensity, divided dosing, biomarker-guided stopping rules, and whether select ocular FIP cases can safely complete shorter courses, but the evidence base for that remains limited today. (wormsandgermsblog.com)